Table 1

Characteristics of lung tumors

TypeaKRASbTP53 stainingcTP53 mutationd
1BATGT70/++
2BATGT80/++
3BATGT70/++E5/154/GGC → GTC
4BATGT80/++E5/154/GGC → GTC
5AD50/++E5/158/CGC → CTC
6AD75/++E5/175/CGC → CTC
E8/280/AGA → ATA
7AD75/++E8/273/CGT → CAT
8BA75/++
9BA75/++E7/249/AGG → ATG
10ADTGT90/++E8/272/GTG → TTG
11BA90/++E5/156/CGC → CCC
12AD70/+E7/249/AGG → ATG
13AD90/+++E7/249/AGG → ATG
E8/273/CGT → CTT
14BA90/++E8/272/GTG → TTG
15AD50/++E5/154/GGC → GTC
16ADGAT50/++E5/153/CCC → CCT
17BA75/++E5/158/CGC → CTC
18BA50/++E5/175/CGC → CTC
E8/280/AGA → ATA
19BA50/++
20BA10/+E8/273/CGT → CTT
21AD50/+
22AD10/++
23BAGTT20/+E5/126/TAC → TGC
E7/260/TCC → CCC
24AD50/++
  • a BA, bronchioloalveolar adenocarcinoma; AD, acinar adenocarcinoma.

  • b Codon 12 wild-type sequence is GGT.

  • c Percentage of positive cells in the tumor/intensity of staining.

  • d Exon/codon/mutation. All were heterozygous except for the mutation in patient 16, which was homozygous. TP53 exons 4–9 were amplified by a multiplex PCR; the products were sequenced by cycle-sequencing, and the sequence was resolved on an automated sequencer.